Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Envoy Medical (COCHW) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Envoy Medical's Cash from Operations fell 6511.63% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 2664.67%. This contributed to the annual value of -$17.9 million for FY2024, which is 502.02% down from last year.
  • Latest data reveals that Envoy Medical reported Cash from Operations of -$4.3 million as of Q3 2025, which was down 6511.63% from -$4.5 million recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's Cash from Operations ranged from a high of $1.1 million in Q3 2023 and a low of -$11.1 million during Q4 2023
  • In the last 4 years, Envoy Medical's Cash from Operations had a median value of -$4.0 million in 2023 and averaged -$3.8 million.
  • Over the last 5 years, Envoy Medical's Cash from Operations had its largest YoY gain of 12092.1% in 2023, and its largest YoY loss of 90810.43% in 2023.
  • Over the past 4 years, Envoy Medical's Cash from Operations (Quarter) stood at -$2.4 million in 2022, then crashed by 368.47% to -$11.1 million in 2023, then skyrocketed by 54.32% to -$5.1 million in 2024, then increased by 14.93% to -$4.3 million in 2025.
  • Its last three reported values are -$4.3 million in Q3 2025, -$4.5 million for Q2 2025, and -$3.7 million during Q1 2025.